

Energy for Today. Opportunities for Tomorrow.

Exchange Listings

CNSX (Canadian National Stock Exchange): **BKS**

US OTC:
BRKDF

Frankfurt:
WKN 871666, W80
ISIN CA0844961080

Share Info

Issued46,139,482
Options1,267,500
Warrants21,370,000
Fully Diluted68,776,982
52-Week Range.....C\$.01 - \$0.06
Recent Price\$0.01



Snapshot

Diversified, growth-oriented venture company pursuing opportunities in the **Oil & Gas** and **Life Sciences** sectors.

- ▷ Oil & gas assets include production and exploration projects in Saskatchewan and Alberta.
- ▷ Recently acquired 2.13% interest in TrichoScience Innovations Inc., a Canadian Life Sciences company that has developed and patented a cell-based procedure to treat hair loss in both men and women.

Oil & Gas - Alberta & Saskatchewan

Berkley holds interests in three natural gas projects in Alberta and one oil project in Saskatchewan.

- ▷ **Crossfield** (Gas - 20% WI) is located just west of the lucrative Crossfield East sour gas field (over a trillion cubic feet produced). Permitting and licensing efforts are ongoing.
- ▷ **John Lake** (Gas - 10% WI) and **Carbon** (Gas - 6%-10% WI) remain steady producers. Revenues have declined due to lower gas prices. John Lake operated by Crescent Energy Partnership; Carbon operated by ATCO Gas.



Life Sciences - Cell Replication to Treat Hair Loss in Men and Women

Berkley holds 2.13% of RepliCel Lifes Inc., a privately-held Life Sciences company based in Vancouver, B.C. RepliCel has developed and patented a new hair cell replication technology called Replifel™ that has the potential to become an effective, non-surgical treatment for pattern baldness and other forms of hair loss in both men and women.

The Replifel™ procedure is based on autologous* cell implantation technology that replicates a patient's hair cells from their own healthy hair follicles. When reintroduced into areas of hair loss, the replicated cells initiate natural hair regeneration. Replifel™ completed its Stage 1 Human Clinical Trials in 2011. Results of the trials are expected to be announced Q1 2012.

*Using a patient's own cells

Investor contact:

Matt Wayrynen
(604) 682.3701
mwayrynen@berkleyresources.com

Head Office:

Suite 900, 570 Granville St
Vancouver, BC V6C 3P1
604.682.3701
info@berkleyresources.com